Literature DB >> 12712467

A multigene test for the risk of sporadic breast carcinoma.

David E Comings1, Radhika Gade-Andavolu, Lawrence A Cone, Donn Muhleman, James P MacMurray.   

Abstract

BACKGROUND: Although the identification of the BRCA1 and BRCA2 genes have been of great interest, these genes account for less than 5% of all breast carcinoma cases. The remaining cases are sporadic. Reanalysis of a large twin study suggested that genetic factors may play a significant role in sporadic breast and other carcinomas. Sporadic breast carcinoma is polygenically inherited. Multiple genes are likely to have an additive effect, each gene accounting for a fraction of the variance. One factor that may have an impact on the development of hormonally responsive breast tumors is the duration of exposure of the breast to estrogen. Therefore, one of the demographic risk factors for breast carcinoma is an early age of onset of menarche. The current study was based on the hypothesis that genes that play a role in demographic risk factors may be breast carcinoma risk genes in their own right. The authors hypothesized that six genes relevant to the timing of the onset of menarche and related risk factors might be candidate genes for breast carcinoma. These were the leptin gene (LEP), the leptin receptor gene (LEPR), the catechol-0-methyltransferase gene (COMT), the dopamine D(2) receptor gene (DRD2), the estrogen 1 receptor gene (ESR1), and the androgen receptor gene (AR).
METHODS: The authors examined 67 women with postmenopausal sporadic breast carcinoma and 145 gender and race-matched controls.
RESULTS: Five of these genes accounted for a significant percent of the variance (r(2)) of breast carcinoma. The following r(2) and P values were calculated: LEP: 0.073, P < or = 0.0001; LEPR: 0.064, P < or = 0.0002; COMT: 0.073, P < or = 0.0001; AR: 0.040, P < or = 0.0035; and DRD2: 0.018, P < or = 0.05. When evaluated in a multivariate regression analysis, they accounted collectively for 24% of the variance of breast carcinoma (P < or = 0.0001). These genes accounted for 40% of the variance (P < or = 0.00001) in a subset of age-matched cases. Individual gene scores were added to form a breast carcinoma risk score (BCRS) that ranged from 0 to 17. When the BCRS was evaluated in a receiver operator characteristic plot, the area under the curve was 0.80 for the full set and 0.869 for the age-matched set. The relative breast carcinoma risk for the different BCRS scores ranged from 0.10 to 11.9.
CONCLUSIONS: These results demonstrate a potentially powerful method of evaluating the additive effect of multiple breast carcinoma risk genes to form a potentially clinically useful assessment of women's risk for sporadic breast carcinoma. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11340

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712467     DOI: 10.1002/cncr.11340

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Oligogenic combinations associated with breast cancer risk in women under 53 years of age.

Authors:  Christopher E Aston; David A Ralph; Dominique P Lalo; Sharmila Manjeshwar; Bobby A Gramling; Daniele C DeFreese; Amy D West; Dannielle E Branam; Linda F Thompson; Melissa A Craft; Debra S Mitchell; Craig D Shimasaki; John J Mulvihill; Eldon R Jupe
Journal:  Hum Genet       Date:  2004-12-21       Impact factor: 4.132

2.  HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.

Authors:  Penney M Gilbert; Janna K Mouw; Meredith A Unger; Johnathon N Lakins; Mawuse K Gbegnon; Virginia B Clemmer; Miriam Benezra; Jonathan D Licht; Nancy J Boudreau; Kelvin K C Tsai; Alana L Welm; Michael D Feldman; Barbara L Weber; Valerie M Weaver
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

3.  Association between the COMT Val158Met polymorphism and breast cancer risk: a meta-analysis of 30,199 cases and 38,922 controls.

Authors:  Xiao-Feng He; Wu Wei; Shao-Xia Li; Jiao Su; Ying Zhang; Xiang-Hua Ye; Yi Liu; Wei Wang
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

4.  DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma.

Authors:  Li Li; Masaki Miyamoto; Yuma Ebihara; Seiji Mega; Ryo Takahashi; Ryunosuke Hase; Hiroyuki Kaneko; Masatoshi Kadoya; Tomoo Itoh; Toshiaki Shichinohe; Satoshi Hirano; Satoshi Kondo
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.352

5.  Meta-analysis of genetic polymorphisms in xenobiotic metabolizing enzymes and their association with breast cancer risk.

Authors:  Tajamul Hussain; Salman Alrokayan; Upadhyay Upasna; Manickam Pavithrakumari; Jaganathan Jayapriya; Vijay Kumar Kutala; Shaik Mohammad Naushad
Journal:  J Genet       Date:  2018-06       Impact factor: 1.166

6.  Principles in genetic risk assessment.

Authors:  Pedro Viana Baptista
Journal:  Ther Clin Risk Manag       Date:  2005-03       Impact factor: 2.423

Review 7.  Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis.

Authors:  Xue Qin; Qiliu Peng; Aiping Qin; Zhiping Chen; Liwen Lin; Yan Deng; Li Xie; Juanjuan Xu; Haiwei Li; Taijie Li; Shan Li; Jinmin Zhao
Journal:  Diagn Pathol       Date:  2012-10-08       Impact factor: 2.644

8.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

9.  Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study.

Authors:  Sara Wedrén; Lovisa Lovmar; Keith Humphreys; Cecilia Magnusson; Håkan Melhus; Ann-Christine Syvänen; Andreas Kindmark; Ulf Landegren; Maria Lagerström Fermér; Fredrik Stiger; Ingemar Persson; John Baron; Elisabete Weiderpass
Journal:  Breast Cancer Res       Date:  2004-06-04       Impact factor: 6.466

Review 10.  Oestrogen exposure and breast cancer risk.

Authors:  Ruth C Travis; Timothy J Key
Journal:  Breast Cancer Res       Date:  2003-07-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.